NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Spyre Therapeutics, Inc. SYRE
12 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
—
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-25.2%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 12-year series below
Revenue
Net income
Per share
—
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-25.2%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-22.4%
Each USD of equity lost 25 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 777.8M
total assets, end of FY2025
Total assetsUSD 777.8M
EquityUSD 715.2M
CashUSD 85.7M
Current ratio13.25×
Equity funds 92% of total assets.
History
12 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
Operating income $B
−0.2
−0.2
−0.2
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.2
−0.2
−0.2
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
−0.0
0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.2
−0.2
−0.3
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
·
·
·
·
·
·
·
·
·
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−25.2
−59.3
−289.2
−124.9
−58.8
−80.9
−122.7
−75.3
−48.1
−106.5
·
·
Shares out B
·
·
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
31 of 31
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed